Glutathione and Cancer: An Honest Look at a Double-Edged Antioxidant

Glutathione and Cancer: An Honest Look at a Double-Edged Antioxidant

Yoon Hang “John” Kim, MD, MPH, FAAMA  • www.directintegrativecare.com

Every month in my integrative oncology practice, a patient asks me some version of the same question: “Should I be taking glutathione?” The question usually comes after they’ve seen an ad, read a wellness article, or heard about IV glutathione from a friend. And the honest answer, after more than two decades in integrative medicine, is: it depends entirely on who you are, what cancer you have, where you are in treatment, and what we’re actually trying to accomplish.

Glutathione is one of those molecules that sounds unambiguously good on the surface — the body’s “master antioxidant,” critical for detoxification, immune function, and cellular defense. But the story inside cancer biology is genuinely more complicated. In the last twelve months alone, two top-tier journals — Nature and Cancer Discovery — have published findings that substantially change how we should think about glutathione in cancer care. This article walks through what the evidence actually says, where I think glutathione still has a legitimate role in integrative oncology, and where I’ve had to rethink my prescribing.

What Glutathione Actually Does

Glutathione (GSH) is a tripeptide — three amino acids, glutamate, cysteine, and glycine, strung together. It is the most abundant non-protein thiol in mammalian tissues, present at millimolar concentrations inside virtually every cell.¹ Its jobs are essential and varied: it neutralizes reactive oxygen species through glutathione peroxidase, conjugates with xenobiotics and drugs to facilitate their detoxification through glutathione-S-transferases, maintains redox balance across cellular compartments, regulates ferroptosis (a specific form of iron-dependent cell death), and participates in immune cell function and protein folding.²

Glutathione exists in two interconvertible forms: reduced (GSH), which performs the antioxidant work, and oxidized (GSSG), which is then recycled back to GSH by glutathione reductase using NADPH. The GSH-to-GSSG ratio is one of the most important indicators of cellular redox status in the human body. When that ratio collapses — either because GSH is depleted or because oxidative stress overwhelms the recycling capacity — cells become vulnerable to damage, mutation, and death.¹·²

So far, this all sounds like an unambiguous argument for keeping glutathione high. The problem is that cancer cells appear to have read the same textbook.

The Dark Side: Why Cancer Loves Glutathione

Here is the core paradox that every integrative oncology clinician needs to internalize. In healthy tissues, adequate glutathione helps defend against the oxidative insults that drive carcinogenesis. But once a malignancy is established, tumor cells frequently upregulate glutathione synthesis and related antioxidant systems as a survival strategy.¹·²·³ Elevated tumor glutathione levels are consistently associated with tumor progression, resistance to chemotherapy, and poorer outcomes across multiple cancer types, including breast, ovarian, liver, and pancreatic cancers.¹·²·⁴

This is not just correlation. A landmark 2015 Nature paper from Sean Morrison’s group at UT Southwestern showed that human melanoma cells experience massive oxidative stress when they enter the bloodstream, and that this oxidative stress is actually what prevents most circulating tumor cells from successfully establishing distant metastases. The cells that do succeed in metastasizing are specifically those that have upregulated antioxidant defenses — and, critically, chronic antioxidant treatment in mouse models increased metastasis formation by human melanoma cells.⁵ Read that sentence again. In that model, antioxidants helped cancer spread.

These findings don’t overturn everything we knew, but they do clarify the mechanism. It is no longer sufficient to say “cancer cells use glutathione to protect themselves from oxidative stress.” The more accurate statement for 2026 is: cancer cells use glutathione in at least three distinct ways — as an antioxidant, as a stress-response signal that enables survival in hostile environments like circulating blood and newly colonized organs, and as a direct nutrient source for cysteine.

Glutathione and Chemotherapy Resistance

One of the most clinically relevant consequences of elevated tumor glutathione is chemotherapy resistance. Many of our most effective cytotoxic drugs — including platinum agents (cisplatin, carboplatin, oxaliplatin), alkylating agents, and certain anthracyclines — rely in part on oxidative damage or on reactive electrophilic intermediates that glutathione can directly inactivate through conjugation.¹ Tumors with high baseline glutathione, high expression of glutathione-S-transferases, or upregulated glutathione export machinery consistently show reduced sensitivity to these drugs.¹·²·⁴

This is why buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, has been studied in clinical trials as a chemosensitizer, and why disulfiram and arsenic trioxide — both of which disrupt glutathione metabolism — have found roles in specific hematologic malignancies. The goal in these strategies is not to restore glutathione; it is to deliberately deplete it in the tumor compartment to re-sensitize resistant cells to chemotherapy.¹

When I counsel a patient who is actively receiving platinum-based or alkylating chemotherapy, I take this seriously. Routinely supplementing high-dose oral or IV glutathione during active cytotoxic treatment has a plausible biological rationale for doing harm to treatment response — even if high-quality clinical proof is limited. That biological caution is enough to change my default.

The Exception: Chemotherapy-Induced Peripheral Neuropathy

There is one clinical scenario where IV glutathione has the most human evidence behind it, and it’s worth being precise about what the data actually show. Chemotherapy-induced peripheral neuropathy (CIPN) is a significant dose-limiting toxicity of platinum drugs and taxanes, affecting roughly a third of patients who complete standard regimens. Beginning in the 1990s, Italian investigators published a series of randomized, placebo-controlled trials showing that IV glutathione (typically 1.5 g/m² before platinum infusion) reduced the incidence and severity of cisplatin-induced and oxaliplatin-induced neuropathy, apparently without reducing the antitumor activity of the chemotherapy.⁶·⁷

Those early trials generated real enthusiasm. But the story got more complicated. A Phase III trial by the North Central Cancer Treatment Group (Leal et al., 2014) found that IV glutathione did not prevent paclitaxel/carboplatin-induced neuropathy — a negative result that contrasted sharply with the pilot data that had led to the trial.⁸ The Cochrane systematic review concluded that, across all the neuroprotectant candidates studied (glutathione, amifostine, calcium/magnesium, vitamin E, N-acetylcysteine, and others), the aggregate evidence was insufficient to recommend any specific agent for routine use in preventing platinum-related neuropathy.⁹ ASCO’s clinical practice guideline on CIPN prevention does not recommend glutathione.

What About Glutathione Supplements?

Outside active cancer treatment, glutathione supplementation is its own nuanced topic. Oral glutathione has historically been considered poorly bioavailable because it is broken down in the gut, though newer formulations — liposomal, acetylated (S-acetyl glutathione), sublingual, and IV — bypass some of these limitations. N-acetylcysteine (NAC), a glutathione precursor, is well-absorbed orally but carries its own considerations in oncology: a widely cited 2014 mouse study found that NAC and vitamin E accelerated lung cancer progression in KRAS-driven and BRAF-driven tumor models, precisely by reducing oxidative stress and p53 activation in premalignant cells.

None of this means glutathione or NAC are categorically off-limits in an integrative practice. I use acetylglutathione in specific non-cancer contexts — mitochondrial support in chronic fatigue, mold recovery, neurodegenerative risk reduction, autoimmune disease, and as part of LDN-based protocols in selected patients. The question is always about context. A patient with chronic Lyme or mold illness and no active malignancy is a different clinical problem than a patient with estrogen-receptor-positive breast cancer in year two post-treatment, and the risk-benefit conversation looks different.

For cancer survivors well past active treatment, the answer is less clear than either the supplement industry or the most conservative oncologists suggest. Some survivors, particularly those with residual chemotherapy-related symptoms, may legitimately benefit from modest, time-limited glutathione support. Others — particularly those with cancers where post-treatment recurrence is a real concern and where preclinical data suggest antioxidants could support residual tumor cell survival — probably should not be on chronic high-dose antioxidants of any kind without a specific reason.

How I Think About Glutathione in Integrative Oncology

My framework, after working with cancer patients breaks down like this:

First, I ask what cancer we’re talking about. Hematologic malignancies behave differently from solid tumors. Hormone-driven cancers behave differently from metabolically-driven cancers. Certain cancers — particularly KRAS-driven lung cancers, advanced melanomas, and metastatic breast cancers — have preclinical signals suggesting heightened risk from antioxidant loading. That background matters.

Second, I ask where we are in the treatment arc. During active chemotherapy, especially with platinum agents, alkylators, or taxanes, my default is caution. If we are specifically trying to mitigate established or emerging neuropathy on cisplatin or oxaliplatin, IV glutathione is a conversation I am willing to have — with the oncology team in the loop. Post-treatment surveillance years are different. Stable long-term survivorship is different again.

Third, I ask what we are actually trying to accomplish. “Boost my antioxidant levels” is not a clinical goal. Specific, measurable goals — reduce emerging neuropathy, support mitochondrial function in post-chemo fatigue, lower markers of oxidative damage tied to specific symptoms, detoxify a specific exposure — are the conversations worth having. If I can’t articulate what we’re targeting, I don’t prescribe.

Fourth, I lean on the Society for Integrative Oncology framework whenever possible. SIO guidelines, endorsed by ASCO, are deliberately conservative, and that conservatism is a feature rather than a limitation when we’re discussing supplements that interact with tumor metabolism. When I step outside SIO-endorsed approaches, I do so deliberately, transparently, and with the patient’s oncology team informed. This is what “honest medicine” looks like in practice.

Finally, I treat the whole patient. Glutathione status is influenced by sulfur amino acid intake (particularly cysteine), sleep quality, alcohol use, acetaminophen burden, environmental toxicant exposure, and the gut microbiome. A cruciferous-vegetable-rich diet, adequate selenium, good sleep, regular exercise, and minimizing exposure to things that deplete glutathione will do more for most patients’ redox status than any supplement — and none of those interventions carry the pro-tumor risk that exogenous glutathione loading does.

The Bottom Line

Glutathione in cancer is genuinely a double-edged sword. It protects normal cells from oxidative damage and plays a legitimate role in detoxification. It also protects tumor cells, supports their survival during metastatic colonization, and in recent work, directly fuels their growth through its catabolism. IV glutathione has the most credible human evidence for reducing platinum-induced neuropathy, but that evidence is more mixed than integrative medicine has often portrayed it, and the most recent large trial was negative. Routine high-dose glutathione supplementation in active cancer treatment is not, in my view, a neutral intervention.

None of this means I’ve stopped using glutathione in my practice. It means I’ve gotten more specific about when, why, and for whom. The best integrative oncology is not the version that reflexively says yes to every antioxidant nor the version that reflexively dismisses supportive therapies. It is the version that reads the primary literature, updates when the data change, respects the patient’s goals, and tells the truth about what we know and don’t know. That’s what I try to do with glutathione, and it’s what I’d want any clinician caring for me or my family to do too.

References

1. Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013). Role of glutathione in cancer progression and chemoresistance. Oxidative Medicine and Cellular Longevity, 2013, 972913. https://doi.org/10.1155/2013/972913

2. Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020). Role of glutathione in cancer: From mechanisms to therapies. Biomolecules, 10(10), 1429. https://doi.org/10.3390/biom10101429

3. Marini, H. R., Facchini, B. A., di Francia, R., Freni, J., Puzzolo, D., Montella, L., Facchini, G., Ottaiano, A., Berretta, M., & Minutoli, L. (2023). Glutathione: Lights and shadows in cancer patients. Biomedicines, 11(8), 2226. https://doi.org/10.3390/biomedicines11082226

4. Park, Y., & Jeong, E. M. (2024). Glutathione dynamics in the tumor microenvironment: A potential target of cancer stem cells and T cells. International Journal of Stem Cells, 17(3), 270–283. https://doi.org/10.15283/ijsc24060

5. Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015). Oxidative stress inhibits distant metastasis by human melanoma cells. Nature, 527(7577), 186–191. https://doi.org/10.1038/nature15726

6. Yeh, H.-W., DelGaudio, N. L., Uygur, B., Millet, A., Khan, A., Unlu, G., Xiao, M., Timson, R. C., Li, C., Ozcan, K., Smith, K. W., Martins Nascentes Melo, L., Allies, G., Basturk, O., Sickmann, A., Bayraktar, E. C., Possemato, R., Tasdogan, A., & Birsoy, K. (2025). Mitochondrial glutathione import enables breast cancer metastasis via integrated stress response signaling. Cancer Discovery, 15(12), 2437–2449. https://doi.org/10.1158/2159-8290.CD-24-1556

7. Hecht, F., Zocchi, M., Tuttle, E. T., Ward, N. P., Alimohammadi, F., Khan, A. A., Gomes, V. C., Smith, B., Twardowski, J. J., Mills, B. N., Welle, K. A., Ghaemmaghami, S., Zhou, Z., Gan, Y., Kang, Y. P., Cazarin, J., Soares, Z. G., Ozgurses, M. E., Zhao, H., … Harris, I. S. (2026). Catabolism of extracellular glutathione supplies cysteine to support tumours. Nature. Advance online publication. https://doi.org/10.1038/s41586-026-10268-2

8. Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., & Catalano, G. (1995). Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology, 13(1), 26–32. https://doi.org/10.1200/JCO.1995.13.1.26

9. Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 20(16), 3478–3483. https://doi.org/10.1200/JCO.2002.07.061

10. Leal, A. D., Qin, R., Atherton, P. J., Haluska, P., Behrens, R. J., Tiber, C. H., Watanaboonyakhet, P., Weiss, M., Adams, P. T., Dockter, T. J., & Loprinzi, C. L. (2014). North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. Cancer, 120(12), 1890–1897. https://doi.org/10.1002/cncr.28654

11. Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews, 2014(3), CD005228. https://doi.org/10.1002/14651858.CD005228.pub4

12. Sayin, V. I., Ibrahim, M. X., Larsson, E., Nilsson, J. A., Lindahl, P., & Bergo, M. O. (2014). Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine, 6(221), 221ra15. https://doi.org/10.1126/scitranslmed.3007653

13. Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. Journal of Clinical Oncology, 38(28), 3325–3348. https://doi.org/10.1200/JCO.20.01399

About the Author

Yoon Hang “John” Kim, MD, MPH, FAAMA is a board-certified preventive medicine physician, Institute for Functional Medicine Certified Practitioner, and fellowship-trained in integrative medicine under Dr. Andrew Weil at the University of Arizona. He previously served as founding Medical Director of Integrative Medicine at Miami Cancer Institute (Baptist Health South Florida), Director of Integrative Medicine at the University of Kansas Medical Center, and Enterprise Medical Director of Integrative Medicine at WellMed/Optum. He currently practices at Hill Country Integrative Medicine in Fredericksburg, Texas, and through Direct Integrative Care (directintegrativecare.com). His clinical work is grounded in Society for Integrative Oncology guidelines with specialized focus on integrative oncology, chronic pain, LDN therapy, and functional medicine.

Disclosure: This article is educational in nature and does not constitute individual medical advice. Patients with active cancer or a history of cancer should make supplementation decisions in consultation with their oncology team.